Literature DB >> 10445609

Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis?

M Drent1, J A Jacobs, J de Vries, R J Lamers, I H Liem, E F Wouters.   

Abstract

The aim of this study was to assess whether the cellular bronchoalveolar lavage fluid (BALF) profile, particularly the number of polymorphonuclear neutrophils (PMNs), is associated with disease severity of sarcoidosis and its usefulness in determining remission. Twenty-six nonsmoking outpatients with sarcoidosis were included in this study. The patients were divided into two subgroups according to the absolute number of PMNs in BALF: < or =0.2x10(4) cells x mL(-1) (group 1; n = 15) and >0.2x10(4) cells x mL(-1) (group 2; n = 11). The radiographic stage, high-resolution computed tomography (HRCT) findings, 67Ga lung uptake as well as lung function tests differed significantly between group 1 and 2. Follow-up revealed that 14 (93.3%) patients of group 1 compared to four (36.4%) of group 2 recovered spontaneously without the help of corticosteroids. In contrast, no differences were found in the number of lymphocytes in BALF nor in the serum angiotensin converting enzyme (sACE) level between both groups. The number of PMNs, the transfer factor of the lungs for carbon monoxide (TL,CO), the forced expiratory volume in one second (FEV1) and one of the HRCT subscores discriminated between patients with different disease progression. Of these parameters the PMNs appeared to be the only one which differentiated patients who demonstrated remission and those who deteriorated. In conclusion, these results indicate that the number of polymorphonuclear neutrophils in bronchoalveolar lavage fluid distinguish between sarcoidosis patients who demonstrated remission and those having a more severe course of the disease. Whether polymorphonuclear neutrophils may be considered as markers of disease activity and/or prognosis in sarcoidosis needs further investigation.

Entities:  

Mesh:

Year:  1999        PMID: 10445609     DOI: 10.1183/09031936.99.13613459

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  17 in total

1.  (18)F-FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis.

Authors:  Ruth G Keijsers; Jan C Grutters; Heleen van Velzen-Blad; Jules M van den Bosch; Wim J Oyen; Fred J Verzijlbergen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-16       Impact factor: 9.236

2.  Risk factors of relapse in pulmonary sarcoidosis treated with corticosteroids.

Authors:  Yi Zheng; Hui Wang; Qingqing Xu; Xin Yan; Yi Zhuang; Hanyi Jiang; Fanqing Meng; Yonglong Xiao; Hourong Cai; Jinghong Dai
Journal:  Clin Rheumatol       Date:  2019-03-15       Impact factor: 2.980

3.  The clinical and immunologic features of pulmonary fibrosis in sarcoidosis.

Authors:  Karen C Patterson; Kyle Hogarth; Aliya N Husain; Anne I Sperling; Timothy B Niewold
Journal:  Transl Res       Date:  2012-04-10       Impact factor: 7.012

4.  Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis.

Authors:  Matthew J Loza; Carrie Brodmerkel; Roland M Du Bois; Marc A Judson; Ulrich Costabel; Marjolein Drent; Mani Kavuru; Susan Flavin; Kim Hung Lo; Elliot S Barnathan; Robert P Baughman
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

5.  Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease.

Authors:  E Fortunati; K M Kazemier; J C Grutters; L Koenderman; van J M M Van den Bosch
Journal:  Clin Exp Immunol       Date:  2008-12-09       Impact factor: 4.330

Review 6.  Clinical and immunologic components of sarcoidosis.

Authors:  Andrea T Borchers; Calvin So; Stanley M Naguwa; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

7.  Sarcoidosis: assessment of disease severity using HRCT.

Authors:  Marjolein Drent; Jolanda De Vries; Merinke Lenters; Rob J S Lamers; Snjezana Rothkranz-Kos; Emiel F M Wouters; Marja P van Dieijen-Visser; Johny A Verschakelen
Journal:  Eur Radiol       Date:  2003-06-17       Impact factor: 5.315

8.  The analysis of tryptase in serum of sarcoidosis patients.

Authors:  Elena Bargagli; Angela Mazzi; Fabrizio Mezzasalma; Anna Perrone; Carmela Olivieri; Antje Prasse; Nicola Bianchi; Maria G Pieroni; Paola Rottoli
Journal:  Inflammation       Date:  2009-10       Impact factor: 4.092

9.  Use of discriminant analysis in assessing pulmonary function worsening in patients with sarcoidosis by a panel of inflammatory biomarkers.

Authors:  Gregorino Paone; Alvaro Leone; Sandro Batzella; Vittoria Conti; Francesco Belli; Laura De Marchis; Alice Mannocci; Giovanni Schmid; Claudio Terzano
Journal:  Inflamm Res       Date:  2012-12-23       Impact factor: 4.575

10.  BAL fluid cells in newly diagnosed pulmonary sarcoidosis with different clinical activity.

Authors:  Edvardas Danila; Laimute Jurgauskiene; Jolita Norkuniene; Radvile Malickaite
Journal:  Ups J Med Sci       Date:  2009       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.